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Abstract: 
 
The next generation of devices for personal healthcare monitoring will comprise molecular 
sensors to monitor analytes of interest in the skin compartment. Transdermal devices based on 
microneedles offer an excellent opportunity to explore the dynamics of molecular markers in 
the interstitial fluid, however good acceptability of these next generation devices will require 
several technical problems associated with current commercially available wearable sensors 
to be overcome. These particularly include reliability, comfort and cost. An essential pre-
requisite for transdermal molecular sensing devices is that they can be fabricated using 
scalable technologies which are cost effective.  
 
We present here a minimally invasive microneedle array as a continuous monitoring platform 
technology. Method for scalable fabrication of these structures is presented. The microneedle 
arrays were characterised mechanically and were shown to penetrate human skin under 
moderate thumb pressure. They were then functionalised and evaluated as glucose, lactate and 
theophylline biosensors. The results suggest that this technology can be employed in the 
measurement of metabolites, therapeutic drugs and biomarkers and could have an important 
role to play in the management of chronic diseases. 
 
Keywords: 
Microneedles, minimally invasive sensors, continuous glucose monitoring (CGM), 
continuous lactate monitoring (CLM), interstitial therapeutic drug monitoring (iTDM) 
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1. Introduction 
 
The current generation of wearable devices for personal wellness monitoring such as the 
Fitbit (Fitbit), UP3 (Jawbone) and SIM band (Samsung) comprise a variety of physical 
sensors that measure parameters such as movement, heart rate, electrocardiogram (ECG), 
galvanic skin response, bioimpedance, and skin temperature. The next generation of wearable 
smart devices will also incorporate non-invasive/minimally invasive molecular sensors. The 
main challenges anticipated for these smart devices would be similar to the ones faced 
currently by the physical sensors particularly in terms of reliability, cost and the ethical issues 
associated with ownership and use of continuous bio-signal obtained in real time. 
 
Transdermal devices consisting of microstructures such as hollow (van der Maaden et al. 
2014), swellable (Ameri et al. 2010) (Yang et al. 2013),  coated (Gill and Prausnitz 2007), 
(Kim et al. 2011), (Vrdoljak et al. 2012),  and solid microneedles (Birchall et al. 2011), 
(Larraneta et al. 2014) (Donnelly et al. 2012) , (van der Maaden et al. 2012), have been used 
mainly for vaccine (van der Maaden et al. 2014), and drug delivery (Sullivan et al. 2008), 
(Kim et al. 2012) but there is a rapidly growing interest in using them for molecular sensing 
(Coffey et al. 2013) ,  (Lee et al. 2014), (Miller et al. 2016; Mukerjee et al. 2004; Trzebinski 
et al. 2012), (El-Laboudi et al. 2013). The interstitial fluid (ISF) in the skin compartment 
exhibits a dynamic exchange of small to medium sized molecules with capillary blood 
thereby offering access to analytes with minimal trauma and in a continuous manner, 
something that could be potentially of great clinical utility. The main application where 
minimally invasive, continuous measurement is of immense value is in continuous glucose 
monitoring for diabetes. However with suitable devices this could also be extended to lactate 
monitoring in athletes for performance training, interstitial therapeutic drug monitoring as 
well as lifestyle related applications such as help in smoking cessation. 
 
Interstitial fluid has been extensively explored for metabolites such as glucose and lactate 
(Ciechanowska et al. 2013; Miller et al. 2012) . Continuous glucose monitoring (CGM) has 
been most intensively studied and there is good clinical evidence that effective CGM in Type 
1 diabetes leads both to a reduced frequency of hypoglycaemic episodes and lowered HbA1c 
(Pickup et al. 2011). 
 
Minimally invasive, continuous monitoring of lactate in the interstitial fluid could also offer a 
more informative measure of this metabolite that would allow athletes to monitor it during 
their training rather than taking a single (venous blood) measurement at the end (Goodwin et 
al. 2007).  
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The ISF microenvironment also offers a compartment in which to measure the dynamics of 
therapeutic drugs and biomarkers during treatment. There are reports suggesting that there are 
as many as 80 molecular markers in the skin compartment that show good correlation with 
venous blood (Paliwal et al. 2013). A recent study in animals has shown a good correlation 
between the concentration and dynamics of many drugs in ISF and venous blood (Kiang et al. 
2012). Therapeutic drug monitoring in the interstitial fluid using minimally invasive devices 
for continuous or periodical monitoring of drugs with narrow therapeutic index offers a 
potential route to personalisation of medication regimes.  
 
Despite the promise of minimally invasive continuous monitoring, experience with CGM 
using some of the approved commercial devices such as those from Medtronic (Enlite), 
Dexcom (G5) and Abbott (FreeStyle Libre) has revealed that their uptake is still less than 
10% despite nearly two and half decades of research and development (Lodwig et al. 2014), 
(Heinemann et al. 2012). This can be attributed mainly to poor accuracy and precision (giving 
rise to many false alarms) and high costs of device manufacture. Current CGM devices are 
mostly subcutaneously implanted and hence the emphasis has been on long term 
performance. Our approach has been to use a minimally invasive microneedle array format 
where the sensors can be readily and painlessly inserted and where the cost is sufficiently low 
that daily replacement is feasible. This could give all the proven benefits of continuous 
monitoring at a price comparable to the current single measurement strips. We report here on 
methods used for fabrication of such microneedle arrays. 
 
To achieve the low cost and scalable manufacture injection molding of polycarbonate yielded 
300-microneedle structures/hour. Mechanical characterization of these structures is presented 
and their functionalization to produce glucose, lactate and theophylline biosensors is 
described. The in vitro characterisation of these, as well as in vivo studies on human skin 
illustrates their performance. 
 
 2.0 Experimental section: 
 
2.1. Materials:  
 
Cu-W, Aluminium blocks and hardened stainless steel stamps were obtained from Erodex,UK 
respectively. Phenol was obtained from Sigma-Aldrich, UK. Glucose oxidase (Glucose 
Oxidase HPS300, Sekisui Diagnostics (U.K), Ltd, Units, Activity 239U/mg powder @25
o
C, 
source Ex Aspergillus niger) and lactate oxidase (Lactate Oxidase II, Sekisui Diagnostics 
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(U.K), Ltd, Units, Activity 41U/mg powder @37
o
C, source Ex Aerococcus vinidans) were 
employed as the enzymes for glucose and lactate sensors respectively. Xanthine oxidase 
(Xanthine Oxidase microbial, Sigma Aldrich U.K, >7U/mg powder) was used for the 
theophylline sensor. 
 
2.2. Fabrication of the base microneedle array:  
 
Copper-Tungsten and stainless steel masters, fabricated using electric discharge milling 
(EDM), were then used as electrodes for spark erosion of aluminum blocks to create molds. 
The spark erosion was repeated up to six times. In one instance, the molds were washed with 
a pressurized jet to remove the eroded debris. In another example, the aluminum mold created 
by EDM was pressed against a hardened stainless steel master. For the injection moulding, a 
hydraulic injection-moulding machine (Victory 28, Engel) was used to manufacture the 
samples. The moulded parts were manufactured in polycarbonate (Makrolon OD2015) which 
was dried at 110 °C for 24 for hours under vacuum prior to use. The EDM prepared 
aluminium master inlay was inserted into the tool which was designed to produce parts 
measuring ≈25 × 25 × 2 mm or 25 × 25 × 1 mm. For the manufacturing of the part, we 
applied the following conditions to the injection moulding process: Tm = 270°C (PC melt 
temperature), Tw = 80°C (tool temperature), vi = 20 cm
3
 s
−1
(injection speed), shot volume of 
4.4 cm
3
 and a cooling time (tc) of 5 seconds. This resulted in a total cycle time 12 second for 
each sample. 
 
 2.3. SEM characterisation:  
 
The bare devices were sputtered with 50nm chromium and imaged using a JEOL 5610 
scanning electron microscope.  
 
2.4. Mechanical evaluation: 
 
2.4.1. Measurement of axial compression force 
 
The effect of applying an axial compression load to the microneedle array was assessed using 
an Instron 5866 instrument with a 500 N load cell. Microneedle arrays were placed on a fixed 
metal plate with the microneedles facing upwards before applying the desired force through 
the movable probe of the Instron compression system. The Instron instrument applied 
pressure on the microneedle arrays using an axial force (parallel to the microneedles’ axes) at 
a rate of 1mm/s until the required force was exerted. Forces ranging from 50N to 400N were 
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tested. Scanning electron microscopy of microneedle arrays were obtained before and after 
application of the compression load. The height of each microneedle was measured after 
testing and the percentage change in microneedle height calculated.  
 
2.4.2. Measurement of transverse fracture force: 
 
The transverse failure forces of microneedle arrays were measured with the same force station 
as described above. A thin probe (Agar Scientific) (2 mm thickness at the tip) was slotted in 
the clamp and used for this purpose. It was adjusted to ensure that it pressed orthogonally 
against a row of eight microneedles. The probe was moved at a speed of 1 mm/min. The force 
required to fracture a single microneedle was determined by dividing the transverse force 
required to fracture one row by the number of microneedles in each row (four). The 
microneedle arrays were examined by scanning electron microscopy prior to and after 
fracture testing. 
 
2.5 Functionalisation: 
 Bare microneedle arrays were sputtered with chromium (15 nm)/Platinum (50nm) to obtain 
the working electrodes. One of the microneedle arrays was sputtered with Ag (150nm), which 
was modified to an Ag/AgCl reference electrode by treating with a saturated solution of 
FeCl3. The working electrodes were biased against the integrated Ag/AgCl reference 
electrodes for electropolymerisation and subsequent chronoamperometry measurements. 
The glucose, lactate and theophylline biosensors described here were fabricated using an 
electropolymerisation method. For electropolymerised polyphenols, the electrode was placed 
in 50 mM phenol monomer and 10 mg/mL of GOx/LOx/XOx enzyme dissolved in 100 mM 
PBS. The pH of the solution was buffered to pH 7.2. Each cycle comprised of holding the 
working electrode at 0 V for 20 s, polarising it to a potential of 0.9 V for 15 minutes for 
electropolymerisation of the film. Each cycle was repeated six times to obtain the desired film 
thickness and enzyme loading.  
Using 200uL of various concentrations of glucose, lactate and theophylline solutions, 
chronoamperometric measurements were made over 60 seconds. From these measurements, 
dose response curves were obtained for glucose, lactate and theophylline biosensors. 
2.6. Optical Coherence Tomography of Microneedles in human tissue-  
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Unfunctionalised devices were sterilized by subjecting them to 25kGy of Co60 (Synergy 
Health) before the insertion studies. The microneedle array structures were inserted into the 
forearm of volunteers by the application of moderate thumb pressure (<10 Newtons) for 60 
seconds.  
 
Optical coherence tomography (details) based has been reported used by several groups to 
look at the skin penetration.(Donnelly et al. 2010) On removal of the device, OCT equipment 
(Vivosight, Michelson diagnostics) was used to look at the penetration of the stratum 
corneum.  
 
3.0 Results: 
3.1. SEM Characterisation:  
The SEM images were analysed for geometry. Each injection molded part was 20x20mm 
with a 2 mm thick base and comprising 4 arrays each of which had 16 microneedles in a 4x4 
subarray. The individual microneedles were pyramidal in shape; 1000 microns tall, with a 600 
microns square base and a tip diameter of ~40microns. The pitch between the microneedles is 
1200 microns. 
3.2. Mechanical Evaluation 
In axial compression tests (n=4) the microneedles tolerated large forces without fracture. The 
reduction of microneedle height increased non-linearly with increasing applied force. This 
ranged from 1% for 50 N to 17 % for 400 N axial forces. Transverse fracture tests (n=3) 
showed that the force required to fracture one row of four microneedles was 80 ± 3 N (20N 
per microneedle). 
3.3 Functional evaluation:  
The functionalised devices were tested with varying glucose, lactate and theophylline 
concentrations using chronoamperometry. From the chronoamperometry studies the dose 
response curves were fitted to the Michealis-Menten equation.  
Insert Figure 1(a) (b) (c) 
As seen from the dose response curves, glucose and lactate concentration as low as 0.5mM 
could be easily detected.  For the glucose biosensors, the three microneedle electrode arrays 
within a single device exhibited Km values of 11.4+2.7mM, 13.9+5.9mM and 15.5+9.6mM. 
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The corresponding Imax values for the three electrodes were 20.3+2.4µA, 23.6 +5.4µA and 
25.5 +8.7µA.  
Insert Table 1 
The Imax values were found to be low for the lactate and theophylline biosensors. This can be 
attributed to the low activity of the enzymes used here (Lactate oxidase 41U/mg powder and 
Xanthine oxidase 7U/mg powder @37
o
C). With the lactate biosensors, the microneedle array 
electrodes exhibited Km values of 3.03+0.9mM with the epoxy polyurethane (PU) membrane 
and 0.7+0.08mM respectively. The Imax values for the two electrodes were 2.5+0.2µA and 
0.95+0.06µA respectively. Similarly, the theophylline biosensors exhibited Km values of 
31+1.22µM with the epoxy polyurethane (PU) membrane and 13+1.84µM respectively. The 
Imax values for the two electrodes were 0.52+0.05µA and 0.31+0.008 µA respectively.  
Whilst the increase in linear range is expected for a mass transport limiting membrane, it 
would also be expected to reduce the maximum current. A possible explanation for the 
increased limiting currents is that the membrane reduces the rate of diffusion of hydrogen 
peroxide away from the electrode surface, resulting in an increased local concentration 
quickly consequently leading to a higher current. 
3.4. Insertion Test on human skin: The insertion ratio, as determined from the tests (n=16) in 
vivo (human skin) was 100% for very moderate forces (<10 Newton). Whilst the SEM of the 
microneedle arrays following insertion tests confirmed the structural integrity of the device 
the OCT images confirm the penetration of the stratum corneum.  
Insert Figure 2(a), (b), (c), (d) & (e) 
It is observed that the channels created by penetration of microneedles collapse on account of 
the highly elastic nature of the skin layers therefore OCT was done with device inserted. 
4.0 Conclusions:  
Next generation wearable devices will carry minimally invasive, continuous monitoring 
systems for metabolites, biomarkers and drugs and will have implications for the better 
management of both lifestyle and chronic diseases. We have demonstrated here a scalable 
(300/hr) and cost effective approach to fabricating polycarbonate-based (material cost of 2 
pence) microneedle structures with desired geometry and mechanical properties. The 
sterilized structures were tested on human skin and it was observed that the geometry of the 
tips allowed penetration of the stratum corneum and access to the dermal interstitial fluid by 
insertion under moderate thumb pressure. The microneedle arrays could subsequently be 
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functionalised to perform as electrochemical biosensors. 
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7. Captions for figures and table: 
 
Figure 1: Dose-response curves obtained for glucose, lactate and theophylline. Figure 8(a) is 
a dose-response curve obtained from three working electrodes functionalised with glucose 
oxidase entrapped in polyphenol but without an epoxy PU membrane. In 8(b) and 8(c) the red 
curves are for working electrodes coated with epoxy PU membrane and the black curves are 
for working electrodes without the membrane.  
Table 1: Showing the Michelis-Menten KM constant and the maximum limiting current Imax 
for the three biosensors.  
Figure 2: (a) Showing image of the polycarbonate microneedle array sputtered with 50nm 
platinum. (b) & (c) Scanning electrochemical microscope images of the microneedle at 100X 
and 500X magnification. (d) Optical coherence tomographic image showing the section of 
tissue with one embedded microneedle as seen here the microneedle penetrates 800 microns 
deep into the skin. (e) Graphics produced in ImageJ using the 3D Viewer’ plugin showing a 
row of the microneedles embedded in the tissue. 
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Figure 1: 
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Figure 2: 
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Table 1:  
 
Biosensor Enzyme Km Imax
Theophylline Biosensor Xanthine oxidase (7U/mg)
With epoxy PU membrane 31 µM +  1.22 0.52 µA + 0.05
Without membrane 13µM + 1.84 0.31µA + 0.008
Lactate Biosensor Lactate oxidase (41U/mg)
With epoxy PU membrane 3.03mM + 0.9 2.5µA + 0.2
Without membrane 0.7mM + 0.08 0.95µA + 0.06
Glucose Biosensor Glucose oxidase (239U/mg)
WE1 No membrane 11.4mM + 2.74 20.3µA + 2.45
WE2 No membrane 13.9mM + 5.9 23.6µA + 5.4
WE3 No membrane 15.5mM + 9.6 25.5µA + 8.71  
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Highlights 
 
Rapid, low cost prototyping of transdermal devices for personal healthcare 
monitoring” by Sanjiv Sharma, Anwer Saeed, Christopher Johnson, Nikolaj 
Gadegaard and Tony Cass 
 
 Microneedle structure based minimally invasive, transdermal sensors for 
measuring analytes (metabolites, drug) in the dermal compartment 
 These microneedle structures are fabricated by injection molding technology that 
has the potential for mass production  
 Microneedle structures are mechanically robust against transverse and axial forces 
 Microneedle structures penetrate human skin and sit in the dermal interstitial 
space under moderate thumb pressure (<10Newtons) 
 Microneedle array structures can be easily modified to glucose , lactate and 
theophylline biosensor devices 
